Nabriva Therapeutics recruit new COO
pharmafile | July 12, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Nabriva Therapeutics, biotech, drugs, pharma, pharmaceutical
Nabriva Therapeutics, a pharmaceutical company that is developing new antibiotics for the treatment of serious infections, has brought Francesco Maria Lavino to the company from MSD to perform the role of Chief Commercial Officer.
Lavino joins the company having managed MSD’s anti-bacterial portfolio, in varying positions sales and marketing positions. In total, he spent over 12 years at MSD, where he progressed from Marketing Manager for the Cardiovascular Market to Associate Vice President and Global Brand Leader Antibiotics Portfolio. He also had close to two years’ experience as Cubist Pharmaceuticals’ Vice President of International Marketing.
Lavino commented on his appointment to the new role: “There has been a dearth of innovation in the development of new anti-infective medicines…Nabriva Therapeutics is poised to introduce what is potentially the first new class of antibiotics for systemic human use in nearly two decades. I am looking forward to working with Will, Colin and the rest of the management team to address serious medical needs in lung, skin, and potentially other types of infections.”
Lavino refers to the Phase 3 global clinical trials for lefamulin, a semi-synthetic antibiotic for community-acquired bacterial pneumonia. Should the antibiotic succeed in these trials, Lavino would be responsible for the marketing of the drug to doctors on a regional and national basis.
“Nabriva Therapeutics is on the cusp of a major inflection point, as we work toward the potential approval of the first pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia,” said Colin Broom, CEO. “Francesco has the right experience and leadership qualities to build out a fully integrated commercial team and hospital field force in the United States, and I am delighted to welcome him as part of our team.”
Related Content
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
